中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2009年
5期
356-358
,共3页
张慧明%崔修铮%李智宇%王一澎
張慧明%崔脩錚%李智宇%王一澎
장혜명%최수쟁%리지우%왕일팽
脾脏%淋巴瘤%外科手术%临床特征
脾髒%淋巴瘤%外科手術%臨床特徵
비장%림파류%외과수술%림상특정
Spleen%Lymphoma%Surgical procedures,operative%Clinical characteristics
目的 分析原发性脾脏恶性淋巴瘤的临床特征.方法 回顾性分析2000年11月至2008年8月收治的29例脾脏原发性恶性淋巴瘤患者的临床资料. 结果29例患者中,非霍奇金淋巴瘤27例,霍奇金淋巴瘤2例.根据Ahmann脾淋巴瘤临床分期,Ⅰ期6例,Ⅱ期4例,Ⅲ期19例.26例患者进行了脾脏切除术,2例因病变侵犯胰尾而行脾脏切除+胰体尾切除术,1例因侵犯胃行脾脏切除+部分胃切除术.术后19例患者接受了辅助性化学治疗,5例使用利妥昔单抗(美罗华).1例患者接受了区域淋巴结放射治疗.中位随访时间24个月(2～93个月),脾脏原发性恶性淋巴瘤1、3和5年的总生存率分别为:96%、83%和73%,1、3和5年的无瘤生存率分别为96%、51%和51%.结论 脾脏原发性恶性淋巴瘤是最常见的原发性脾脏恶性肿瘤,手术切除脾脏及其周围受累器官是重要的治疗方法,手术后应当辅以化疗、放疗、生物治疗等措施.
目的 分析原髮性脾髒噁性淋巴瘤的臨床特徵.方法 迴顧性分析2000年11月至2008年8月收治的29例脾髒原髮性噁性淋巴瘤患者的臨床資料. 結果29例患者中,非霍奇金淋巴瘤27例,霍奇金淋巴瘤2例.根據Ahmann脾淋巴瘤臨床分期,Ⅰ期6例,Ⅱ期4例,Ⅲ期19例.26例患者進行瞭脾髒切除術,2例因病變侵犯胰尾而行脾髒切除+胰體尾切除術,1例因侵犯胃行脾髒切除+部分胃切除術.術後19例患者接受瞭輔助性化學治療,5例使用利妥昔單抗(美囉華).1例患者接受瞭區域淋巴結放射治療.中位隨訪時間24箇月(2～93箇月),脾髒原髮性噁性淋巴瘤1、3和5年的總生存率分彆為:96%、83%和73%,1、3和5年的無瘤生存率分彆為96%、51%和51%.結論 脾髒原髮性噁性淋巴瘤是最常見的原髮性脾髒噁性腫瘤,手術切除脾髒及其週圍受纍器官是重要的治療方法,手術後應噹輔以化療、放療、生物治療等措施.
목적 분석원발성비장악성림파류적림상특정.방법 회고성분석2000년11월지2008년8월수치적29례비장원발성악성림파류환자적림상자료. 결과29례환자중,비곽기금림파류27례,곽기금림파류2례.근거Ahmann비림파류림상분기,Ⅰ기6례,Ⅱ기4례,Ⅲ기19례.26례환자진행료비장절제술,2례인병변침범이미이행비장절제+이체미절제술,1례인침범위행비장절제+부분위절제술.술후19례환자접수료보조성화학치료,5례사용리타석단항(미라화).1례환자접수료구역림파결방사치료.중위수방시간24개월(2～93개월),비장원발성악성림파류1、3화5년적총생존솔분별위:96%、83%화73%,1、3화5년적무류생존솔분별위96%、51%화51%.결론 비장원발성악성림파류시최상견적원발성비장악성종류,수술절제비장급기주위수루기관시중요적치료방법,수술후응당보이화료、방료、생물치료등조시.
Objective To analyze the clinical features of primary splenic lymphoma. Method Clinicopatholngie features of 29 patients with primary splenic lymphoma treated in Cancer Hospital, Chinese Academy of Medical Sciences from November 2000 to August 2008 were analyzed retrospectively. Results In this study 27 cases were confirmed to be non-Hodgkin's lymphoma (NHL), and 2 cases were of Hodgkin's lymphoma (HL). According to Ahmann's staging, 6 cases belonged to stage Ⅰ, 4 was stage Ⅱ, and 19 was stage Ⅲ. Twenty-six patients received spleneetomy, 2 cases did splenectomy plus pancreatic body and tail resection, and 1 case did spleneetomy plus partial gastrectomy. Postoperatively, 19 cases received chemotherapy, and 5 of the 19 patients received rituximab (Mabthera) treatment. One patient received radiotherapy for regional lymph node invasion. The median time of follow-up was 24 months (range, 2 -93 months). The l-year, 3-year and 5-year overall survival rates were 96%, 83% and 73%, respectively. The 1-year, 3-year and 5-year disease-free survival rates were 96%, 51% and 51%, respectively. Conclusions Primary splenic lymphoma is the most common malignant tumor of the spleen. Splenectomy combined with excision of invaded tissues or organs is important therapy for patients with primary splenic lymphoma. Comprehensive treatments including chemotherapy, radiotherapy and biotherapy are recommended after operation.
